Skip to the content
 
  • Payment Plans
  • Login for Professionals
  • English
    • Deutsch
    • Français
    • Italiano
    • English
  • Healthy Travelling
  • Countries
  • News
  • Special travellers
  • Health risks
  • Vaccinations
  • Ask a specialist

MENU

  • LogIn
  • English
    • Deutsch
    • Français
    • Italiano
    • English
  • Healthy Travelling
  • Countries
  • News
  • Special travellers
  • Health risks
  • Vaccinations
  • Ask a specialist
 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

 

Health Advice for Travellers
Swiss Expert Committee for Travel Medicine

The HealthyTravel team wishes you a Merry Christmas and a happy 2026 with travels in good health.

 

9722540.jpg

The US CDC has updated the areas at risk for chikungunya. As of 16 December, there is a chikungunya travel health notice for outbreaks in:

  • Bangladesh
  • Cuba
  • Guangdong Province, China
  • Sri Lanka

 

Countries considered to have an elevated risk for chikungunya include:

  • Brazil
  • Bolivia*
  • Colombia
  • India
  • Mexico
  • Nigeria
  • Pakistan
  • Philippines
  • Thailand

*According to news (see under ‘Bolivia’) increased transmission is also seen in Bolivia.

In addition to optimal mosquito bite prevention, the Swiss ECTM recommendation include:

 

Chikungunya vaccination is recommended for:

  • Persons >12 years of age travelling to an area with a chikungunya outbreak (see current outbreaks list of US CDC).
  • Laboratory workers who might be exposed to the virus.

 

Chikungunya vaccination may be considered for:

  • Persons >12 years travelling or moving to an area with elevated risk for chikungunya (see list of countries with elevated risk of US CDC) if planning to stay for an extended period of time or repeated stays (for example, cumulative period of 3 months or more).

Of note:

  • Two chikungunya vaccines have been licensed in Europe but not yet in Switzerland.
  • Consultation with a travel or tropical medicine specialist is advised.
  • For details, see ECTM statement for chikungunya recommendation or SOP.
CDC, 16.12.2025 | Swiss ECTM

Although global activity remains within expected seasonal ranges, early increases and higher activity than typical at this time of year have been observed in some regions.

 

Seasonal influenza viruses, including A(H3N2) viruses, continually evolve over time. Since August 2025, there has been a rapid increase of A(H3N2) J.2.4.1 alias K subclade viruses detected from several countries based on available genetic sequence data. These subclade K viruses have several changes from related A(H3N2) viruses. Current epidemiological data do not indicate an increase in disease severity, although this subclade marks a notable evolution in influenza A(H3N2) viruses. Early estimates suggest that the influenza vaccine continues to provide protection against hospital attendance in both children and adults, even though its effectiveness against clinical disease during the current season remains uncertain.

Practice regular hand hygiene. Reminder: At risk person should be vaccinated against influenza, RSV and SARS-Cov2 according to national guidelines. For Switzerland, see new FOPH Recommendation for RSV.
WHO DON, 10.12.2025 | PAHO, 11.12.2025

Media, citing local health authorities, report that the Departmental Health Service (Sedes) has issued a health alert following an active chikungunya outbreak in the Cochabamba tropics. Rubén Castillo, Head of Epidemiology, confirmed 100 cases, 81 of which are locally acquired, along with 40 suspected cases currently under investigation. The cases are primarily concentrated in the municipalities of Entre Ríos, Villa Tunari, and Puerto Villarroel. Authorities warned that transmission in the region continues to rise.

 

According to the European Center of Disease Control, chikungunya cases have been reported from six of nine departments with Santa Cruz to be the most affected one.

Optimal mosquito bite prevention 24/7, also for other mosquito-borne diseases.

 

Chikungunya vaccination may be considered for:

  • Persons >12 years travelling or moving to an area with elevated risk for chikungunya (see list of countries with elevated risk of US CDC) if planning to stay for an extended period of time or repeated stays (for example, cumulative period of 3 months or more).

Of note:

  • Two chikungunya vaccines have been licensed in Europe but not yet in Switzerland.
  • Consultation with a travel or tropical medicine specialist is advised.
  • For details, see ECTM statement for chikungunya recommendation or SOP.
ECDC, 17.12.2025 | ATB, 9.12.2025
In 2025, Hong Kong reported 11 locally acquired chikungunya cases as of 10 December 2025. Six of these were epidemiologically linked to the Tsing Yi Nature Trails, and genetic analysis revealed identical viral sequences, suggesting ongoing local transmission.

Optimal mosquito protection 24/7, also in cities, see factsheet: Optimal mosquito and tick bite protection 24/7. This also protects you against other mosquito-borne diseases. Vaccination against chikungunya is not licensed in Switzerland.

 

For vaccination recommendations, see ECTM statement.  

Government of Hong Kong, 9.12.2025 | Via BEACON, 12.12.2025

Get in touch with us

  • Sekretariat Schweizerische Fachgesellschaft für Tropen- und Reisemedizin,
    Socinstrasse 55, Postfach, 4002 Basel

  • info@healthytravel.ch
  • Ask a specialist
  • News
  • Contact
  • Payment Plans
  • Sponsors
  • Legal notice

Copyright © 2026. All Rights Reserved

0

Bookmarks